Errors in Table. In the Clinical Sciences article titled “Risks of Mortality, Myocardial Infarction, Bleeding, and Stroke Associated With Therapies for Age-Related Macular Degeneration” by Curtis et al, published in the October issue of the Archives (2010;128[10]:1273-1279), there were errors in Table 4 on page 1277. The corrected Table appears below.
Table 4.Unadjusted and Adjusted Outcomes at 1 Year for the Comparison of Ranibizumab Therapy vs Bevacizumab Therapy
Adverse Event
No. of Adverse Events/No. (%) of Patients in the Treatment Group
Hazard Ratio (95% Confidence Interval)RanibizumabBevacizumabUnadjustedAdjustedaJuly to December 2006bAll-cause mortality647/19026 (4.1)833/21815 (4.7)0.87 (0.76-0.99)0.86 (0.75-0.98)Incident myocardial infarction170/19026 (1.1)227/21815 (1.3)0.84 (0.64-1.08)0.83 (0.64-1.08)Bleeding943/19026 (5.8)1017/21815 (5.6)1.04 (0.92-1.16)1.03 (0.92-1.16)Incident stroke289/19026 (1.8)405/21815 (2.2)0.80 (0.65-0.97)0.78 (0.64-0.96)Exclusive ProviderscAll-cause mortality197/4821 (4.7)225/6147 (4.3)1.11 (0.87-1.43)1.10 (0.85-1.41)Incident myocardial infarction47/4821 (1.1)69/6147 (1.3)0.86 (0.53-1.41)0.87 (0.53-1.41)Bleeding225/4821 (5.3)279/6147 (5.2)1.02 (0.81-1.29)1.01 (0.80-1.28)Incident stroke90/4821 (2.1)129/6147 (2.4)0.88 (0.62-1.26)0.87 (0.61-1.24)
aHazard ratios for ranibizumab compared with bevacizumab after adjustment for the variables listed in Table 1.
bBy the end of the study period, almost all newly treated patients received ranibizumab or bevacizumab as first-line therapy. Therefore, in this secondary analysis, the study population was limited to newly treated patients who received ranibizumab or bevacizumab between July and December 2006.
cPatients with higher socioeconomic status may have been more likely to receive ranibizumab vs bevacizumab, so the primary analysis may have been subject to selection bias. Therefore, in this secondary analysis, the study population was limited to patients who received ranibizumab or bevacizumab in a medical practice that performed at least 20 injections and used a single drug in 95% or more of all intravitreous injections during the third or fourth quarter of 2006.